MTI Ltd. Revises FY2026 Earnings Forecast Down on Growth Investments
MTI Ltd. (TSE:9438) has lowered its operating profit and ordinary income guidance for the fiscal year ending September 2026, citing increased development spending and promotional costs tied to healthcare business expansion.
| Item | Before | After | Change |
|---|---|---|---|
| Revenue (JPY M) | 31,500 | 31,500 | — |
| Operating Profit (JPY M) | 3,100–3,500 | 2,700 | △400–△800 |
| Ordinary Income (JPY M) | 3,400–3,800 | 3,100 | △300–△700 |
| Net Profit (JPY M) | 2,560–2,840 | 2,680 | △160–+120 |
| EPS (JPY/share) | 44.29–49.33 | 48.25 | — |
The company maintained its revenue forecast at JPY 31.5bn, reflecting on-track execution. However, operating profit and ordinary income (keijo rieki)—a Japan-specific metric combining operating profit with non-operating items—were cut by JPY 0.4bn–0.8bn and JPY 0.3bn–0.7bn respectively. The downward revision stems from elevated development costs for a next-generation cloud-based pharmacy digital transformation system and increased promotional spending for “Luna Luna Mirai Support” premium courses as prefectural partnerships expand.
Net profit guidance narrowed to JPY 2.68bn, within the prior range’s midpoint, supported by an anticipated JPY 0.524bn tax refund recorded as extraordinary income. After accounting for corporate tax effects, this special gain offsets the operating profit decline, leaving bottom-line earnings largely stable.
The revision underscores MTI’s strategic pivot toward healthcare services, with near-term margin pressure offset by revenue stability and one-time tax benefits. International investors should note that ordinary income differs materially from operating profit due to financial income and expenses, a distinction critical when comparing Japanese earnings to IFRS or US GAAP metrics. The company’s willingness to invest in growth initiatives while maintaining sales guidance suggests confidence in medium-term healthcare business potential.
Source: Original filing (TDnet) | 日本語版
This article is for informational purposes only and does not constitute investment advice. Always verify against the original filing.